Mesoblast plans new GvHD trial after another FDA rejection
Mesoblast plans follows an FDA response to the BLA resubmission for remestemcel-L for treating pediatric steroid-refractory acute GvHD.
Mesoblast plans follows an FDA response to the BLA resubmission for remestemcel-L for treating pediatric steroid-refractory acute GvHD.
What's Your Reaction?
